Please assess the completion status of the following clinical trial:

Trial Title: Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Patients scheduled for either elective unilateral or same-day bilateral total knee replacement surgery (TKR) or a revision of at least 1 component of a TKR~* Patients willing and able to undergo bilateral ascending contrast venography~Key Exclusion Criteria~* Known or suspected hereditary or acquired bleeding or coagulation disorders in the participant or his or her first-degree relative~* Known or suspected history of heparin-induced thrombocytopenia~* Known coagulopathy~* Active bleeding or at high risk for bleeding~* Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days~* Active hepatobiliary disease~* Alcohol and/or substance abuse within the past year~* Any condition for which, in the opinion of the investigator, surgery or administration of an anticoagulant was contraindicated~* Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic blood pressure \>180 mm Hg or supine diastolic blood pressure \>105 mm Hg~* Clinically significant laboratory abnormalities at the enrollment visit:~  * Hemoglobin \<10 g/dL~ * Platelet count \<100,000/mm\^3~ * Creatinine clearance \<30 mL/min, as estimated by the method of Cockcroft and Gault~ * Alanine aminotransferase or aspartate aminotransferase level \>2\*upper limit of normal (ULN) or a total bilirubin ≥1.5\*ULN (unless an alternative causative factor such as Gilbert's syndrome was identified)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban, 2.5 mg BID + Placebo (Type: EXPERIMENTAL): Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
- Enoxaparin, 40 mg QD + Placebo (Type: ACTIVE_COMPARATOR): Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).